HGI 001
Alternative Names: HGI-001Latest Information Update: 24 May 2023
At a glance
- Originator Shenzhen Hemogen
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Beta-thalassaemia
Most Recent Events
- 27 May 2022 Phase-0 for Beta-thalassaemia (In adults) in China (Parenteral) (NCT05864170)
- 01 Dec 2020 Phase-0 clinical trials in Beta-thalassaemia (In children, In adolescents) in China (Parenteral) (NCT05745532)